- Report
- February 2024
- 70 Pages
Egypt
From €4315EUR$4,750USD£3,679GBP
- Report
- February 2024
- 70 Pages
United Kingdom
From €4315EUR$4,750USD£3,679GBP
- Report
- February 2024
- 70 Pages
France
From €4315EUR$4,750USD£3,679GBP
- Report
- February 2024
- 70 Pages
Saudi Arabia
From €4315EUR$4,750USD£3,679GBP
- Report
- February 2024
- 70 Pages
South Africa
From €4315EUR$4,750USD£3,679GBP
- Report
- February 2024
- 70 Pages
Mexico
From €4315EUR$4,750USD£3,679GBP
- Report
- February 2024
- 70 Pages
Brazil
From €4315EUR$4,750USD£3,679GBP
- Report
- February 2024
- 70 Pages
Russia
From €4315EUR$4,750USD£3,679GBP
- Report
- February 2024
- 70 Pages
Japan
From €4315EUR$4,750USD£3,679GBP
- Report
- August 2023
- 70 Pages
Africa, Middle East
From €4315EUR$4,750USD£3,679GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4315EUR$4,750USD£3,679GBP
- Report
- October 2022
- 70 Pages
Africa
From €4315EUR$4,750USD£3,679GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4315EUR$4,750USD£3,679GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4315EUR$4,750USD£3,679GBP
- Report
- February 2024
- 160 Pages
Middle East, Africa
From €4315EUR$4,750USD£3,679GBP
- Report
- February 2024
- 90 Pages
Europe
From €4315EUR$4,750USD£3,679GBP
- Report
- February 2024
- 70 Pages
Latin America
From €4315EUR$4,750USD£3,679GBP
- Report
- February 2024
- 70 Pages
United States
From €4315EUR$4,750USD£3,679GBP
- Report
- February 2024
- 70 Pages
Spain
From €4315EUR$4,750USD£3,679GBP
- Report
- February 2024
- 70 Pages
Vietnam
From €4315EUR$4,750USD£3,679GBP

Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. It is a member of the Endocrine and Metabolic Disorders Drugs class, which are used to treat a variety of conditions related to hormones and metabolism. Lixisenatide works by stimulating the release of insulin from the pancreas, helping to reduce blood sugar levels. It is typically used in combination with other diabetes medications, such as metformin or sulfonylureas.
Lixisenatide is available in both injectable and oral formulations. The injectable form is administered once daily, while the oral form is taken once weekly. Common side effects of lixisenatide include nausea, diarrhea, and headache. It is important to note that lixisenatide should not be used in patients with type 1 diabetes or diabetic ketoacidosis.
Some companies in the Lixisenatide market include Sanofi, Eli Lilly, and Novo Nordisk. Show Less Read more